We have located links that may give you full text access.
English Abstract
Journal Article
Meta-Analysis
[The relationship between prion protein gene codon 129 polymorphism and Alzheimer's disease].
OBJECTIVE: To examine the relationship between prion protein gene (PRNP) codon 129 polymorphism and Alzheimer's disease (AD) by means of meta-analysis.
METHODS: Odds ratios (OR) of prion protein gene codon 129 genotype distribution in AD patients against healthy control was analysed. All the relevant studies were identified and poor-qualified studies were eliminated. A meta-analysis software, Review Manager 4.2 was applied for investigating heterogeneity among individual studies and summarizing effects across studies.
RESULTS: A total of 4 studies including 1095 patients and 940 controls were included but with rectification 972 cases and 658 controls of 3 studies were included. No heterogeneity among the studies was found. The pooled Peto OR (with 95% CI) of (MM + VV) vs MV is 1.10 (95% CI 0.89-1.35, P = 0.38), while the pooled Peto OR of V* vs MM is 0.80 (95% CI 0.65-0.98, P = 0.03) and the pooled Peto OR of M* vs VV is 1.38 (95% CI 1.01-1.89, P = 0.04).
CONCLUSION: In European population, PRNP M and V homozygosity is not statistically significantly associated with the onset of AD. M/* genotype is associated with increased risk of AD while V/* genotype is associated with a decreased risk of AD.
METHODS: Odds ratios (OR) of prion protein gene codon 129 genotype distribution in AD patients against healthy control was analysed. All the relevant studies were identified and poor-qualified studies were eliminated. A meta-analysis software, Review Manager 4.2 was applied for investigating heterogeneity among individual studies and summarizing effects across studies.
RESULTS: A total of 4 studies including 1095 patients and 940 controls were included but with rectification 972 cases and 658 controls of 3 studies were included. No heterogeneity among the studies was found. The pooled Peto OR (with 95% CI) of (MM + VV) vs MV is 1.10 (95% CI 0.89-1.35, P = 0.38), while the pooled Peto OR of V* vs MM is 0.80 (95% CI 0.65-0.98, P = 0.03) and the pooled Peto OR of M* vs VV is 1.38 (95% CI 1.01-1.89, P = 0.04).
CONCLUSION: In European population, PRNP M and V homozygosity is not statistically significantly associated with the onset of AD. M/* genotype is associated with increased risk of AD while V/* genotype is associated with a decreased risk of AD.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app